PF 055

Drug Profile

PF 055

Alternative Names: PF-055

Latest Information Update: 23 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Renaissance Pharma
  • Developer Mylan
  • Class Antiparasitics; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Scabies

Most Recent Events

  • 22 Mar 2017 No recent reports of development identified - Phase-II for Scabies (In adolescents, In children, In infants, In adults) in USA (Topical)
  • 25 Mar 2014 Phase-II clinical trials in Scabies (In infants, children, adolescents and adults) in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top